Dendritic cells, loaded with recombinant bacteria expressing tumor antigens, induce a protective tumor-specific response

Maria Rescigno, Barbara Valzasina, Roberto Bonasio, Matteo Urbano, Paola Ricciardi-Castagnoli

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Dendritic cells (DCs) are considered the most potent antigen-presenting cells and probably the only ones able to prime naive T cells. Indeed, DCs are distributed in tissues that interface the external environment, where they act as sentinels for incoming bacteria, viruses, and fungi. We have previously analyzed the capacity of DCs to interact with bacteria, and we have shown that bacteria can act as "Trojan horses," delivering heterologous proteins to DCs in a processed form that allows extremely efficient loading of both MHC class I and class II molecules. In this study, we have optimized the usage of recombinant bacteria as an antigen delivery system for DCs, with the aim to develop a new DC vaccination strategy in antitumor immunity. We have focused on a low immunogenic antigen, the tyrosinase-related protein-2 (Trp-2), a self-antigen expressed in mouse and human melanoma for which induction of antitumor immunity has proven to be very ineffective. We have given mice injections of either Trp-2/recombinant bacteria-loaded DCs or with bacteria alone engineered to express the Trp-2 melanoma antigen. We have shown that only DCs loaded with recombinant bacteria, but not with wild-type bacteria, were able to induce Trp-2-specific CTLs and immunity against the B16 tumor. Immunity was obtained in experiments of tumor vaccination as well as in experiments of tumor therapy. When therapy with bacteria-loaded DCs was performed in B16 tumor-bearing mice, 60% of the treated mice were tumor free 2 months after the initial tumor growth.

Original languageEnglish
JournalClinical Cancer Research
Volume7
Issue number11 SUPPL.
Publication statusPublished - Mar 2001

Fingerprint

Neoplasm Antigens
Dendritic Cells
Bacteria
Neoplasms
Immunity
Vaccination
Melanoma-Specific Antigens
Antigens
Autoantigens
Antigen-Presenting Cells
Melanoma
Fungi
Viruses
T-Lymphocytes
Injections
dopachrome isomerase
Therapeutics
Growth

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Dendritic cells, loaded with recombinant bacteria expressing tumor antigens, induce a protective tumor-specific response. / Rescigno, Maria; Valzasina, Barbara; Bonasio, Roberto; Urbano, Matteo; Ricciardi-Castagnoli, Paola.

In: Clinical Cancer Research, Vol. 7, No. 11 SUPPL., 03.2001.

Research output: Contribution to journalArticle

Rescigno, Maria ; Valzasina, Barbara ; Bonasio, Roberto ; Urbano, Matteo ; Ricciardi-Castagnoli, Paola. / Dendritic cells, loaded with recombinant bacteria expressing tumor antigens, induce a protective tumor-specific response. In: Clinical Cancer Research. 2001 ; Vol. 7, No. 11 SUPPL.
@article{567ba372533648ec8937e16ac94ce42c,
title = "Dendritic cells, loaded with recombinant bacteria expressing tumor antigens, induce a protective tumor-specific response",
abstract = "Dendritic cells (DCs) are considered the most potent antigen-presenting cells and probably the only ones able to prime naive T cells. Indeed, DCs are distributed in tissues that interface the external environment, where they act as sentinels for incoming bacteria, viruses, and fungi. We have previously analyzed the capacity of DCs to interact with bacteria, and we have shown that bacteria can act as {"}Trojan horses,{"} delivering heterologous proteins to DCs in a processed form that allows extremely efficient loading of both MHC class I and class II molecules. In this study, we have optimized the usage of recombinant bacteria as an antigen delivery system for DCs, with the aim to develop a new DC vaccination strategy in antitumor immunity. We have focused on a low immunogenic antigen, the tyrosinase-related protein-2 (Trp-2), a self-antigen expressed in mouse and human melanoma for which induction of antitumor immunity has proven to be very ineffective. We have given mice injections of either Trp-2/recombinant bacteria-loaded DCs or with bacteria alone engineered to express the Trp-2 melanoma antigen. We have shown that only DCs loaded with recombinant bacteria, but not with wild-type bacteria, were able to induce Trp-2-specific CTLs and immunity against the B16 tumor. Immunity was obtained in experiments of tumor vaccination as well as in experiments of tumor therapy. When therapy with bacteria-loaded DCs was performed in B16 tumor-bearing mice, 60{\%} of the treated mice were tumor free 2 months after the initial tumor growth.",
author = "Maria Rescigno and Barbara Valzasina and Roberto Bonasio and Matteo Urbano and Paola Ricciardi-Castagnoli",
year = "2001",
month = "3",
language = "English",
volume = "7",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "11 SUPPL.",

}

TY - JOUR

T1 - Dendritic cells, loaded with recombinant bacteria expressing tumor antigens, induce a protective tumor-specific response

AU - Rescigno, Maria

AU - Valzasina, Barbara

AU - Bonasio, Roberto

AU - Urbano, Matteo

AU - Ricciardi-Castagnoli, Paola

PY - 2001/3

Y1 - 2001/3

N2 - Dendritic cells (DCs) are considered the most potent antigen-presenting cells and probably the only ones able to prime naive T cells. Indeed, DCs are distributed in tissues that interface the external environment, where they act as sentinels for incoming bacteria, viruses, and fungi. We have previously analyzed the capacity of DCs to interact with bacteria, and we have shown that bacteria can act as "Trojan horses," delivering heterologous proteins to DCs in a processed form that allows extremely efficient loading of both MHC class I and class II molecules. In this study, we have optimized the usage of recombinant bacteria as an antigen delivery system for DCs, with the aim to develop a new DC vaccination strategy in antitumor immunity. We have focused on a low immunogenic antigen, the tyrosinase-related protein-2 (Trp-2), a self-antigen expressed in mouse and human melanoma for which induction of antitumor immunity has proven to be very ineffective. We have given mice injections of either Trp-2/recombinant bacteria-loaded DCs or with bacteria alone engineered to express the Trp-2 melanoma antigen. We have shown that only DCs loaded with recombinant bacteria, but not with wild-type bacteria, were able to induce Trp-2-specific CTLs and immunity against the B16 tumor. Immunity was obtained in experiments of tumor vaccination as well as in experiments of tumor therapy. When therapy with bacteria-loaded DCs was performed in B16 tumor-bearing mice, 60% of the treated mice were tumor free 2 months after the initial tumor growth.

AB - Dendritic cells (DCs) are considered the most potent antigen-presenting cells and probably the only ones able to prime naive T cells. Indeed, DCs are distributed in tissues that interface the external environment, where they act as sentinels for incoming bacteria, viruses, and fungi. We have previously analyzed the capacity of DCs to interact with bacteria, and we have shown that bacteria can act as "Trojan horses," delivering heterologous proteins to DCs in a processed form that allows extremely efficient loading of both MHC class I and class II molecules. In this study, we have optimized the usage of recombinant bacteria as an antigen delivery system for DCs, with the aim to develop a new DC vaccination strategy in antitumor immunity. We have focused on a low immunogenic antigen, the tyrosinase-related protein-2 (Trp-2), a self-antigen expressed in mouse and human melanoma for which induction of antitumor immunity has proven to be very ineffective. We have given mice injections of either Trp-2/recombinant bacteria-loaded DCs or with bacteria alone engineered to express the Trp-2 melanoma antigen. We have shown that only DCs loaded with recombinant bacteria, but not with wild-type bacteria, were able to induce Trp-2-specific CTLs and immunity against the B16 tumor. Immunity was obtained in experiments of tumor vaccination as well as in experiments of tumor therapy. When therapy with bacteria-loaded DCs was performed in B16 tumor-bearing mice, 60% of the treated mice were tumor free 2 months after the initial tumor growth.

UR - http://www.scopus.com/inward/record.url?scp=0035287770&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035287770&partnerID=8YFLogxK

M3 - Article

C2 - 11300484

AN - SCOPUS:0035287770

VL - 7

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 11 SUPPL.

ER -